104 results about "Statin" patented technology

The invention discloses a traditional Chinese medicine composition with an effect of improving artery blood vessel plaque and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine. The technical problem to be solved is to provide a traditional Chinese medicine composition capable of improving vascular plaques such as carotid artery, aortic arch, brachial trunk, subclavian artery and the like aiming at the current situation that adverse reactions exist when statin lipid-lowering drugs and antiplatelet drugs are taken for a long time to treat artery vascular plaques. According to the technical scheme, the traditional Chinese medicine composition with the effect of improving the artery blood vessel plaque is characterized by comprising radix puerariae, red yeast rice, folium cortex eucommiae, hippophae rhamnoides leaves and natto.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The invention provides a culture medium for improving Klotho protein secreted by mesenchymal stem cells and application of the culture medium, and particularly, the culture medium comprises a basic culture medium, statins and a ROCK inhibitor. The culture medium can effectively improve the Klotho protein secretion level of the mesenchymal stem cells, does not affect the biological activity of the mesenchymal stem cells, and ensures the biological function integrity of the mesenchymal stem cells; meanwhile, operation is easy, cost is low, and good clinical application value is achieved.

The application discloses an inhibitor for inhibiting KRAS phase separation to play an anti-tumor role and application, and relates to the fields of tumor molecular biology and targeted therapy.The application aims at solving the problems of limited effect, strong drug resistance and limited application range of KRAS tumor treatment methods, and the inhibitor is a statin.The KRAS protein can form a liquid condensate in cells, and the application discloses the mechanism of the KRAS protein in promoting KRAS protein processing, transportation and downstream signal activation, and further provides a technical scheme for inhibiting tumor growth and enhancing the therapeutic effect of a KRAS inhibitor by inhibiting the formation of KRAS condensates, so as to provide a new target and intervention approach for tumor treatment.

This invention relates to the field of ovarian tissue in vitro culture technology, and discloses a formulation for activating and increasing follicles and its application. The formulation consists of a PI3K / Akt / mTOR pathway activator and / or a PTEN inhibitor SF1670. The PI3K / Akt / mTOR pathway activator is a 5-15 μM statin, and the PTEN inhibitor is a 20-50 μM SF1670. Using this formulation can achieve the follicle activation and increase effect of existing technologies, contributing to the development and selection of in vitro follicle activators in clinical practice. Furthermore, the use of this formulation opens up a new technological application area for statins.

A method of treating a wound may include topically administering a statin composition including a statin selected from atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, or combination thereof. The statin composition may be administered in an ointment, powder, or liquid format. The method may also include topically administering one or more antimicrobial drugs.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

Described herein is a method of treating biliary tract cancer (BTC) comprising administering a bispecific antigen-binding construct targeting HER2 or a bispecific antigen-binding construct targeting HER2 linked to an auristatin analogue (ADC) to a subject.

Provided herein are compositions, systems, and methods for treating wounds with the combination of statins and cholesterol to help prevent and reduce scar formation.

A preparation method of a tumor microparticle encapsulating a metabolic inhibitor includes following steps. A tumor cell is cultivated, and a statin drug is added to a culture medium after the tumor cell grows stably. Then, the tumor cell is irradiated with an ultraviolet, and then the tumor cell is incubated in a cell incubator for 22˜26 hours. After the incubation, cell supernatant is collected and the tumor microparticle encapsulating the metabolic inhibitor is obtained through a gradient centrifugation. The preparation method uses tumor cell-derived microparticles as drug delivery platforms, with a simple preparation process that preserves functions such as biosafety, biocompatibility, targeting, and intercellular communication. The preparation method discovers new uses of a statin drug, which can inhibit tumor growths with the statin drug, regulate tumors metabolism and improve a tumor microenvironment, and have a potential to enhance a chemotherapy efficacy and delay a chemotherapy resistance.

Disclosed herein are therapeutics compositions including one or more active agents, for instance a statin, cyclodextrin, or combination thereof. The compositions are useful in the treatment of tissue injuries, including wounds, as well as skin inflammation and infections.

The invention belongs to the technical field of medicine. The invention particularly relates to application of statin combined with a KRAS inhibitor in preparation of a medicine for treating colorectal cancer. The invention provides a new effective strategy for treatment of the KRAS inhibitor drug-resistant colorectal cancer, namely a medication scheme of statin combined with the KRAS inhibitor, can significantly improve the treatment effect of the drug-resistant colorectal cancer, effectively inhibit the growth of tumor cells, inhibit the proliferation of tumors, and improve the treatment effect of the KRAS inhibitor drug-resistant colorectal cancer. The KRAS mutant colorectal cancer has an excellent treatment effect on the KRAS mutant colorectal cancer generating drug resistance to a first-line chemotherapy regimen, overcomes the clinical treatment difficulty caused by KRAS mutation, and has a very good application prospect.

The invention belongs to the technical field of chromatographic detection, and provides a simvastatin detection method and application thereof. According to the detection method disclosed by the invention, qualitative and quantitative detection of simvastatin in a sample can be realized by adopting a high performance liquid chromatography-tandem mass spectrometry mode. In the high performance liquid chromatography detection, the simvastatin possibly existing in the red yeast rice powder and the product thereof can be detected by combining a pentafluorophenyl propyl chromatographic column and a formic acid methanol mobile phase. The detection method provided by the invention can effectively distinguish the statins and simvastatin naturally existing in the red yeast rice powder, and can effectively avoid the false positive result of simvastatin detection; the method can also be applied to detection of various products including capsules, tablets, oral liquid and the like containing the red yeast rice powder, and various quality monitoring scenes can be considered.

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.

The invention discloses an efficient composite immobilized enzyme for preparing ethyl R (-)-4-cyano-3-hydroxybutyrate and a preparation method of the efficient composite immobilized enzyme, and relates to the technical field of biological catalysis. The composite immobilized enzyme comprises an active enzyme component, a Nicoordination modified mesoporous silica-chitosan composite carrier, and a sodium alginate auxiliary embedding-glutaraldehyde covalent cross-linking composite immobilization mode. The preparation method comprises the following steps: preparing a modified carrier, preparing an active enzyme mixed solution, carrying out an embedding-crosslinking reaction, collecting and drying. The compound immobilized enzyme can catalytically prepare ethyl R (-)-4-cyano-3-hydroxybutyrate, the substrate conversion rate is still kept at an extremely high level after the compound immobilized enzyme is repeatedly used for more than 15 times, and the compound immobilized enzyme is stable in enzyme activity, low in cost and suitable for industrial green production of statin drug intermediates.

The present invention relates to a pharmaceutical combination comprising 6α-ethyl-3α, 7 a-dihydroxy-24-nor-5 β-cholan-23-ol or a pharmaceutically acceptable salt thereof and a statin and to a combination comprising 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol and ursodesoxycholic acid and the use thereof for the treatment of non-alcoholic liver steatosis and non-alcoholic steatohepatitis.

Described herein are methods for reducing or preventing blood flow in a neurovascular blood vessel of a subject. The method involves injecting a composition composed of water, one or more polycationic polyelectrolytes and anionic counterions, one or more one polyanionic polyelectrolytes and cationic counterions, and a statin, an anti-cancer agent, or a combination thereof, wherein the composition has an ion concentration that is (i) sufficient to prevent association of the polycationic polyelectrolytes and the polyanionic polyelectrolytes in water and (ii) greater than the concentration of ions in the subject. Upon introduction of the composition into a subject, a solid is produced in situ. The injectable compositions have unique distal penetration properties, which make the injectable compositions described herein very useful as embolics for neurovascular blood vessels.

Treatment of cerebral arterial thrombosis with pravastatin is disclosed. The pravastatin adopts an inhalation administration mode or targeted pulmonary administration, so that the aggregation of the medicine in the lung can be enhanced, the infiltration of brain immune cells can be inhibited, the inflammation of the brain parenchyma stroke part can be alleviated, the injury of the nervous system of the stroke part can be improved, and the recovery of the damaged nerve function can be promoted.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating atherosclerosis and a preparation method thereof. The traditional Chinese medicine composition for treating atherosclerosis is prepared from the following raw materials in parts by weight: 20 to 40 parts of radix astragali seu hedysari, 7 to 10 parts of radix notoginseng, 10 to 20 parts of poria cocos, 5 to 15 parts of lotus leaves, 10 to 15 parts of raw fructus crataegi, 10 to 20 parts of radix salviae miltiorrhizae, 10 to 15 parts of radix angelicae sinensis and 2 to 10 parts of ramulus cinnamomi. The traditional Chinese medicine composition can intervene in the atherosclerosis process through multiple ways of adjusting the blood fat level, improving aorta pathological injury, inhibiting inflammatory response, increasing intestinal flora diversity and the like, and the comprehensive treatment effect of the traditional Chinese medicine composition is equivalent to that of clinical conventional medicine statins.

The application discloses a preparation method of high-proportion open-loop statin red koji for regulating blood fat and blood vessel plaques, and belongs to the technical field of microbial fermentation and functional food / medicine. The method takes Monascus purpureus CGMCC No. 18110 as a starting strain, and high-proportion open-loop monacolin K red koji powder is prepared by a core process of compound metabolic regulation substrate preparation + phased variable-temperature gradient oxygen supply fermentation and combined with precise post-processing technology. The total monacolin K content in the obtained red koji powder is greater than or equal to 8 mg / g, the open-loop monacolin K proportion is greater than or equal to 85%, and the citrinin content is less than or equal to 50 ppb. The red koji disclosed by the application can significantly inhibit HMG-CoA reductase activity, realize efficient blood fat regulation, and stabilize, resolve and repair blood vessel endothelium through multi-target synergistic effect, and can be widely applied to the preparation of functional food, medicinal preparations and special medical use formula food. The process has the advantages of high product proportion, high safety, strong process stability and controllable cost, solves the technical pain points of low open-loop rate, large liver and kidney burden and insufficient safety of existing red koji products, and has good industrialization prospect and market value.

The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

The application provides a method for improving 2-deoxy-D-ribose-5-phosphate aldolase (DERA) activity through immobilization. The method can significantly activate the aldolase activity of DERA, and is simple, mild, simple and easy to operate, and can be applied to preparation of chiral side chains of statins.

This invention relates to a method for treating patients with heterozygous familial hypercholesterolemia (heFH), comprising administering a pharmaceutical composition containing a PCSK9 inhibitor to a patient with heterozygous familial hypercholesterolemia. In some embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, such as the exemplary antibody referred to herein as mAb316P. The method of the present invention can be used to treat patients with heterozygous familial hypercholesterolemia whose cholesterol is poorly controlled with the maximum tolerated dose of statins, with or without other lipid-lowering therapy.

The invention relates to the technical field of biological detection, in particular to polypeptide, a kit and a method for detecting mouse statin. The invention provides a specific synthetic polypeptide with an amino acid sequence as shown in SEQ ID NO: 1, and the synthetic polypeptide is used as a substance with clear chemical definition and replaces natural protein which is complex in structure and difficult to preserve in a traditional double-antibody sandwich method, so that inherent inter-batch difference and quality fluctuation of a biological source standard substance are eliminated from the source. Based on the core reagent, the competitive ELISA detection system constructed by the invention achieves the technical effects of strong specificity, high accuracy and good repeatability, and meanwhile, as the synthetic polypeptide can realize low-cost and high-throughput chemical synthesis, the development period of the whole detection scheme is greatly shortened, and the economical efficiency is remarkably improved.

The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.